| Bioactivity | JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells[1]. |
| Target | IC50: 0.32 nM (CX3CR1) |
| In Vivo | JMS-17-2 (10 mg/kg; aministered i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice[1]. Animal Model: |
| Name | JMS-17-2 |
| CAS | 1380392-05-1 |
| Formula | C25H26ClN3O |
| Molar Mass | 419.95 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. |
JMS-17-2
CAS: 1380392-05-1 F: C25H26ClN3O W: 419.95
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and co
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.